ClinicalTrials.gg
Not yet recruitingNCT01894308PARC-T-DUpdated Sep 30, 2026

A Dose Ranging Study to Examine TDS-Testosterone 5%

A Phase 2 interventional study of Testosterone and Pump Sprayer in Hypogonadotropism, sponsored by Transdermal Delivery Solutions Corp. Not yet recruiting at 1 site in United Kingdom. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Transdermal Delivery Solutions Corp · Phase 2, Interventional, and Treatment

How we know

Updated Sep 30, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 119 studies testing testosterone in Hypogonadism — 9 open to participants now, 11 under way, 3 of them phase 3. Testosterone · Hypogonadism.

Planned enrollment
60th of 116
48 · median 49
Started
2027
with 1 other
Phase 2
33 of 119
4 open now
Primary completion
2027-10
later than 6 of 10 live
Registered
73rd of 119
by date

Among the 119 studies testing testosterone in Hypogonadism, this one is the 60th largest by planned enrollment of the 116 interventional ones that give a count, is one of 2 that started in 2027, is one of 33 in phase 2, reaches primary completion later than 6 of the 10 other live ones, and was the 73rd registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

9 of the 119 studies testing testosterone in Hypogonadism are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About testosterone

Testosterone: first FDA approval 1953 (DELATESTRYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies testing testosterone in Hypogonadism, or all of them as a file.
02

Study summary

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

Read the detailed description

48 Patients will be enrolled following 2 independent verifying blood tests of their diagnosis of Hypogonadism. there will be 4 cohorts of 12 subjects, each receiving doses of the trail materials, titrated by means of number of sprays applied. Doses will range from 10 to 70 mgs Testosterone.

03

Conditions studied

  • Hypogonadotropism

Browse trials for

Keywords

  • Male Hormone Replacement
  • Multiple Dose
  • Single Period
  • Phase II
  • Dose Ranging
  • Adult Male Subjects
  • Testosterone Replacement
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hypogonadal Male subjects - morning testosterone level ≤300 ng/dL (10.4 ng/L).
  2. 18 and 75 years of age, inclusive.
  3. The subject is willing and able to read, understand the Subject Information Sheet and provide written .
  4. The subject has a (BMI) within 18-30 kg/m2.
  5. The subject is in otherwise good health as determined by medical history and physical examination.
  6. The subject is a non-smoker.
  7. The subject must agree to comply with the placement of an indwelling catheter on two separate occasions and the drawing of blood samples for the pharmacokinetic assessments.
  8. The subject is willing and able to comply with all testing and requirements defined in the protocol.
  9. The subject is willing and able to return to the study site for all visits.

Exclusion criteria

Exclusion Criteria:

  1. The subject has any relevant deviations from normal in physical examination, (ECG), or clinical laboratory tests, as evaluated by the investigator, particularly an elevated PSA reading >4.0 ng/ml or and AST greater than 2 times the , anemia (hematocrit \<35%) or renal dysfunction (creatinine >2mg/dL), active deep vein thrombosis, thromboembolic disorders or history of these conditions.
  2. The subject has had a clinically significant illness within 30 days preceding entry into this study.
  3. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
  4. The subject has a known allergy or history of to Testosterone or similar compounds.
  5. The subject has used any prescription medication within 14 days or over-the-counter (OTC) medication or alcohol within 48 hours of dosing or intends to use any prescription or OTC medication during the study that may interfere with the evaluation of study medication.
  6. The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and their concentration and haematocrit have not returned to within 5% of normal.
  7. The subject has a Hematocrit level > 51%
  8. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
  9. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
  10. Subjects who have received an drug or have used an investigational device in the 30 days prior to study entry.
  11. Subjects with an American Urological Association System Index for Prostatism score greater than 7
  12. Subjects with a history of prostate or breast carcinoma.
  13. Subjects with prostatic mass on screening physical examination.
  14. Subjects with a history of significant skin disease.
  15. Subjects with a history of sleep apnea.
  16. Subject with a partner with a history of breast cancer.
  17. Subject with a partner of child bearing potential who is not willing to use adequate for the duration of the trial.
  18. Subject whose partner is pregnant.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Forearm dose

    Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.

    Drug: Testosterone · Device: Pump Sprayer

  • Active comparator
    Chest Dose

    Half of Ss will receive their dose of Testosterone on the chest.

    Drug: Testosterone · Device: Pump Sprayer

Interventions

  • 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

  • DevicePump Sprayer

    A dose of product solution is delivered by means of a metered pump spray.

06

What researchers measure

Primary outcomes

  1. Dose Range Measure of serum levels of testosterone in response to varying doses

    A pharmacokinetic measure of serum levels of testosterone in response to varying doses of from 10 to 70 mgs of Testosterone.

    Time frame: 1 week

Secondary outcomes

  1. Dermal Safety as measured by

    Incidence of treatment-emergent side effects.

    Time frame: 1 Week

07

Study locations

1 site
  • Advanced Therapies Centre, The London Clinic
    London, NW1 4LJ, United Kingdom
08

References and documents

Publications

  • Chik Z, Johnston A, Tucker AT, Chew SL, Michaels L, Alam CA. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br J Clin Pharmacol. 2006 Mar;61(3):275-9. doi: 10.1111/j.1365-2125.2005.02542.x. PubMed 16487220 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jun 2027; primary completion for Oct 2027, 4 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Jun 2026 → Jun 2027, primary completion Oct 2026 → Oct 2027 and completion Feb 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2013
First posted
Jul 10, 2013
StartEst.
Jun 2027was Jun 2026
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Feb 2028was Feb 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Jun 2027
Sep 30, 2026
Primary completion
Oct 2026→Oct 2027
Sep 30, 2026
Study completion
Feb 2027→Feb 2028
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Jun 2026→Jun 2027
    Primary completion Oct 2026→Oct 2027
    Study completion Feb 2027→Feb 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01894308
Lead sponsor
Transdermal Delivery Solutions Corp
Collaborators
Advanced Therapies Centre, The London Clinic
Responsible party
Sponsor
First posted
Jul 10, 2013
Start date
Jun 2027 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Shern L. Chew, M.D., Ph.D.
Contact
sl.chew@thelondonclinic.co.uk
011-44-20 034 6227
Chandan AS Alam, MD
Contact
calam@tdsc.us
011-44-7785-717596
Shern L. Chew, M.D., Ph.D.
principal investigator · Consultant Physician and Professor of Endocrine Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Testosterone

Start the discussion